inclusion criteria: * the subject is willing and able to provide informed consent prior to any study procedure. * age at the time of screening between 18 and 85 years inclusive. * coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) or immunochromatographic detection of sars cov-2 specific antigens no more than three days prior to randomization. * covid-19 symptoms lasting less than or equal to seven days, including. * subject is currently hospitalized and requires medical care due to covid-19 disease and was admitted at most two days prior to randomization. * peripheral blood oxygen saturation \<94% on air (as measured by pulse oximetry or arterial blood sampling) at the time of inclusion in the trial.

inclusion criteria: * the subject is willing and able to provide informed consent prior to any study procedure. * age at the time of screening between 18 and 85 years inclusive. * coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) or immunochromatographic detection of sars cov-2 specific antigens no more than three days prior to randomization. * covid-19 symptoms lasting less than or equal to seven days, including. * subject is currently hospitalized and requires medical care due to covid-19 disease and was admitted at most two days prior to randomization. * peripheral blood oxygen saturation \<94% on air (as measured by pulse oximetry or arterial blood sampling) at the time of inclusion in the trial.

inclusion criteria: the subject is willing and able to provide informed consent prior to any study procedure. age at the time of screening between 18 and 85 years inclusive. coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) or immunochromatographic detection of sars cov-2 specific antigens no more than three days prior to randomization. covid-19 symptoms lasting less than or equal to seven days, including. subject is currently hospitalized and requires medical care due to covid-19 disease and was admitted at most two days prior to randomization. peripheral blood oxygen saturation <94% on air (as measured by pulse oximetry or arterial blood sampling) at the time of inclusion in the trial.

inclusion criteria: the subject is willing and able to provide informed consent prior to any study procedure. age at the time of screening between 18 and 85 years inclusive. coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) or immunochromatographic detection of sars cov-2 specific antigens no more than three days prior to randomization. covid-19 symptoms lasting less than or equal to seven days, including. subject is currently hospitalized and requires medical care due to covid-19 disease and was admitted at most two days prior to randomization. peripheral blood oxygen saturation <94% on air (as measured by pulse oximetry or arterial blood sampling) at the time of inclusion in the trial.